Related Experiment Videos
[Liver disorders in patients with Mycoplasma pneumoniae pneumonia]
Y Watanabe1, H Kanayama, K Kato
1Department of Internal Medicine, Kamo Hospital, Toyota, Japan.
Abstract:
Liver disorders were reviewed in 76 patients with mycoplasma pneumoniae pneumonia (MP) admitted to Kamo Hospital from 1979 to 1989. Liver dysfunction was detected in 16 patients (21%). Liver disorder were detected in 10% of MP from 1979 to 1980, but in 20% from 1984 to 1985, and in 36% from 1988 to 1989. By multiple regression analysis CRP was found to be the most significant factor among other factors such as prevalence, age, sex, history of smoking, history of drinking, and days after onset of fever.
Insights
Mycoplasma pneumoniae pneumonia (MP) can cause liver dysfunction in over 20% of patients. C-reactive protein (CRP) levels were identified as the most significant factor associated with these liver disorders.
Area of Science:
- Hepatology
- Infectious Diseases
- Pulmonology
Context:
- A retrospective review of 76 patients with Mycoplasma pneumoniae pneumonia (MP) admitted to Kamo Hospital between 1979 and 1989.
- Investigated the incidence and characteristics of liver disorders in patients diagnosed with MP.
Purpose:
- To determine the prevalence of liver dysfunction in patients with Mycoplasma pneumoniae pneumonia.
- To identify factors associated with the development of liver disorders in MP patients.
Summary:
- Liver dysfunction was observed in 16 out of 76 patients (21%) diagnosed with MP.
- The incidence of liver disorders showed an increasing trend over the study period (10% in 1979-1980 to 36% in 1988-1989).
- Multiple regression analysis identified C-reactive protein (CRP) as the most significant factor associated with liver disorders, out of factors including prevalence, age, sex, smoking, drinking, and days after fever onset.
Impact:
- Highlights the potential for Mycoplasma pneumoniae to cause significant liver injury.
- Suggests C-reactive protein as a potential biomarker for monitoring liver involvement in MP patients.
- Informs clinical suspicion and management strategies for Mycoplasma pneumoniae pneumonia, particularly regarding potential hepatic complications.